To the full analysis
Chongqing Zhifei Biological Products stock: growth
300122.SZChongqing Zhifei Biological Products reported $1.34B in revenue for fiscal 2025, down 65.6% on the prior year.
Revenue (Annual rate)
17.5%
per year from 2007 to 2025, per share 17%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
24.6%
per year from 2007 to 2025, per share 24.1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2007 | |
|---|---|---|---|
| Revenue | −10.0% | 28.8% | 17.5% |
| Revenue per share | −17.0% | 23.7% | 17.0% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | 11.2% | no data | 24.6% |
| Free cash flow per share | 2.6% | no data | 24.1% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $73.85M | $22.8M | $13.03M |
| 2008 | $88.53M | $28.5M | $15.85M |
| 2009 | $90.59M | $34.73M | $29.8M |
| 2010 | $110.57M | $38.51M | $401.32K |
| 2011 | $94.29M | $29.45M | −$13.24M |
| 2012 | $114.02M | $32.25M | −$12.92M |
| 2013 | $117M | $19.55M | $3.03M |
| 2014 | $120.11M | $22.2M | −$17.33M |
| 2015 | $106.89M | $29.6M | −$339.94K |
| 2016 | $66.88M | $4.88M | −$32.71M |
| 2017 | $201.34M | $64.83M | −$4.08M |
| 2018 | $784.06M | $217.65M | $15.86M |
| 2019 | $1.59B | $354.88M | $119.08M |
| 2020 | $2.28B | $495.08M | $400.36M |
| 2021 | $4.6B | $1.53B | $986.09M |
| 2022 | $5.74B | $1.13B | $80.37M |
| 2023 | $7.94B | $1.21B | $1.18B |
| 2024 | $3.91B | $302.7M | −$801.46M |
| 2025 | $1.34B | −$2.21B | $682.06M |
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 2 May 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.